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Abstract 
Background: Myristoylation of the matrix (MA) domain mediates the transport and binding of Gag polyproteins to 
the plasma membrane (PM) and is required for the assembly of most retroviruses. In betaretroviruses, which assemble 
immature particles in the cytoplasm, myristoylation is dispensable for assembly but is crucial for particle transport 
to the PM. Oligomerization of HIV-1 MA stimulates the transition of the myristoyl group from a sequestered to an 
exposed conformation, which is more accessible for membrane binding. However, for other retroviruses, the effect of 
MA oligomerization on myristoyl group exposure has not been thoroughly investigated.
Results: Here, we demonstrate that MA from the betaretrovirus mouse mammary tumor virus (MMTV) forms dimers 
in solution and that this process is stimulated by its myristoylation. The crystal structure of N-myristoylated MMTV MA, 
determined at 1.57 Å resolution, revealed that the myristoyl groups are buried in a hydrophobic pocket at the dimer 
interface and contribute to dimer formation. Interestingly, the myristoyl groups in the dimer are mutually swapped to 
achieve energetically stable binding, as documented by molecular dynamics modeling. Mutations within the myris-
toyl binding site resulted in reduced MA dimerization and extracellular particle release.
Conclusions: Based on our experimental, structural, and computational data, we propose a model for dimerization 
of MMTV MA in which myristoyl groups stimulate the interaction between MA molecules. Moreover, dimer-forming 
MA molecules adopt a sequestered conformation with their myristoyl groups entirely buried within the interaction 
interface. Although this differs from the current model proposed for lentiviruses, in which oligomerization of MA 
triggers exposure of myristoyl group, it appears convenient for intracellular assembly, which involves no apparent 
membrane interaction and allows the myristoyl group to be sequestered during oligomerization.
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Background
Mouse mammary tumor virus (MMTV), a causative 
agent of mammary breast cancer and T cell lymphomas 
in mice (for review see [1]), is a representative of the 
Betaretrovirus genus. In contrast to HIV-1 and other 
retroviruses that assemble immature particles during 
budding at the plasma membrane (PM), betaretrovi-
ruses assemble immature particles within the cytoplasm 
prior to transport to the PM for budding. In general, 
the hexameric lattice of immature retroviral particles is 
formed by association of 1500 to 2500 molecules of the 
multidomain structural polyprotein Gag. The N-terminal 
domain of Gag, matrix (MA) protein, is responsible for 
Gag targeting and PM binding. During or shortly after 
budding, the viral protease-dependent cleavage of Gag 
initiates rearrangement of individual mature proteins, 
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after which MA molecules remain associated with the 
enveloping membrane and form the outer shell of the 
viral particle [2].
In most retroviruses, the N-terminal glycine residue 
of the MA domain of Gag is co-translationally modi-
fied with myristic acid (reviewed in [3]). Myristoylation 
of MA and the highly basic patch of amino acids located 
near its N-terminus mediate the interaction of Gag with 
the PM. The myristoyl group serves as a hydropho-
bic anchor associated with the lipidic acyl chains in the 
PM, while the positively charged surface patch in MA 
interacts electrostatically with the polar heads of phos-
pholipids. Both the myristoyl group and the basic patch 
function in concert to facilitate efficient MA membrane 
anchoring (for review see [4]). In HIV-1 and other viruses 
that assemble particles at the PM, prevention of myris-
toylation by mutation of the N-terminal glycine to ala-
nine (G2A) dramatically reduces binding of Gag to PM 
and inhibits viral particle formation [5–9]. However, in 
betaretroviruses such as Mason-Pfizer monkey virus 
(M-PMV) and MMTV, the analogous G2A mutation 
does not interfere with the process of intracytoplasmic 
assembly but completely blocks the transport of viral 
particles to the PM [10, 11]. The MA domain not only 
targets the PM and mediates the association of viral par-
ticles, but it also dictates the lipid-binding specificity (for 
review see [12, 13]).
In addition to its role in promoting the association with 
the PM, some other functions have been attributed to the 
MA domain of Gag. In M-PMV, a highly conserved short 
stretch of amino acids within MA domain, termed the 
cytoplasmic targeting/retention signal (CTRS), interacts 
with Tctex-1, a component of the dynein motor machin-
ery [14], and is responsible for intracellular targeting of 
Gag to the pericentriolar region for assembly. Similarly, 
CTRS in the MMTV MA domain was recently found 
to mediate pericentriolar targeting of Gag [15]. Several 
mutations within the M-PMV MA domain can abrogate 
transport of assembled particles to the PM in a manner 
similar to the G2A mutation in Gag, and these changes 
in MA might negatively affect Gag/Env interaction at the 
recycling endosome and prohibit usage of the vesicular 
transport system [16–18]. The lentiviral MA domain may 
be directly involved in incorporation of Env into virions, 
at least for HIV-1 [19].
Structures of MA protein from ten retroviruses have 
been resolved by NMR or X-ray crystallography [20–29]. 
Despite the low sequence homology of these proteins, 
their overall three-dimensional organization is remarka-
bly similar, consisting of a globular core composed of four 
or five α-helices (reviewed in [12]). However, structures 
of myristoylated forms [myr(+)] have been reported only 
for MA proteins from the lentiviruses HIV-1 [30], HIV-2 
[28], feline immunodeficiency virus (FIV) [31], and the 
betaretrovirus M-PMV [32]. The solution structure of 
myr(+) HIV-1 MA revealed an equilibrium between 
a monomeric form with the myristoyl group seques-
tered inside the protein core and a trimeric form with 
exposed myristoyl groups [30]. Transition between the 
monomeric and trimeric states of myr(+) HIV-1 MA is 
entropically regulated, and higher protein concentra-
tion stimulated and stabilized formation of the trimeric 
form [30]. In contrast, nonmyristoylated [myr(−)] HIV-1 
MA appeared mainly in the monomeric state in solution 
[20] but in the trimeric state in crystals [33]. Despite the 
structural similarity between the HIV-1 and HIV-2 MA 
proteins, myristoylation does not influence the trimeri-
zation ability of HIV-2 MA [28]. However, betaretroviral 
MA from M-PMV readily forms oligomers (dimers and 
trimers) in its myr(−) form [34], while myr(+) MA is 
monomeric in solution [32]. Based on extensive studies 
of HIV-1 MA, it is generally accepted that the myristoyl 
group can adopt a sequestered conformation within the 
globular head of MA as well as an exposed conformation 
where it is more accessible and can facilitate membrane 
association. The process of transition between these two 
states, termed the myristoyl switch, can be influenced 
by several factors, including protein concentration, oli-
gomerization status, and pH [30, 35].
Here, we investigated the role of myristoylation on oli-
gomerization of MMTV MA and determined the crystal 
structure of myr(+) MMTV MA, which represents the 
first X-ray structure of a myr(+) retroviral MA protein. 
Our structural data reveal the sequestered conforma-
tion of the myristoyl group bound into the MMTV MA 
dimer interface, and analytical ultracentrifugation and 
molecular dynamics analyses show its crucial role for 
MA dimerization. Based on the structural and molecular 
modeling data, we constructed MMTV MA mutant with 
a reduced ability to form dimers in vitro. Identical muta-
tions were also tested in the context of MMTV virus and 
their impact upon assembly and transport of immature 
particles was analyzed.
Results
Myristoylation stimulates dimerization of MMTV MA 
in solution
Typically, myristoyl group participates in protein subcel-
lular localization by facilitating protein–membrane and 
protein–protein interactions (reviewed in [36]). To deter-
mine the influence of myristoylation on self-association 
of the MA domain of MMTV Gag, we performed ana-
lytical ultracentrifugation using bacterially expressed and 
purified myr(+) and myr(−) MA, containing five C-ter-
minally attached amino acids from the pp21 domain 
followed by a His-tag [37]. The purified myr(+) MA 
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contained less than 0.1 % of myr(−) MA as documented 
by mass spectrometry analysis (Additional file  1: Figure 
S1). Sedimentation velocity experiments were performed 
with recombinant myr(+) and myr(−) MA proteins at 
two different concentrations (0.5 and 5.0 mg/mL), and we 
analyzed their tendency to form oligomers by fitting the 
sedimentation data using a continuous size distribution 
model. The comparison of all resultant size distributions 
is shown in Fig.  1. At the lower concentration, myr(−) 
MA formed one discrete particle with sedimentation 
coefficient s20,w  =  1.57 S. This value corresponds well 
with the mass of the MA monomer, pointing to a mod-
erately elongated particle with approximate dimensions 
of 2–3 ×  4–6  nm. At the higher concentration, myr(−) 
MA formed two particles, corresponding to a monomer 
(s20,w = 1.69 S; 74 %) and a dimer (s20,w = 2.12 S; 26 %). In 
contrast, at the lower concentration, myr(+) MA formed 
only dimers with s20,w  =  2.12 S. At the higher concen-
tration, myr(+) MA predominantly formed dimers 
(s20,w  =  2.27 S; 98  %) but also formed a particle cor-
responding to a tetramer (s20,w = 3.69 S; 2 %). Thus, we 
conclude that the ability of MMTV MA to form dimers is 
stimulated by its myristoylation.
The dimerization of MMTV MA driven by its myris-
toylation also provides a likely explanation for the sepa-
ration of His-tagged myr(+) and myr(−) MMTV MAs 
on an IMAC column that we described previously [37]. 
A dimer of MA has two His-tags which results in higher 
affinity to the IMAC column. The efficiency of the sep-
aration is influenced by the difference in the ability of 
myr(+) and myr(−) MAs to form dimers. The formation 
of myr(+):myr(−) mixed dimers decreases the separation 
efficiency.
Structure of myristoylated MMTV MA
To provide structural evidence for the role of the myris-
toyl group in MA dimerization, we determined the struc-
ture of myr(+) MA prepared by the procedure described 
by Dolezal et  al. [37]. The protein crystallized in the 
P3121 space group with two molecules in the asym-
metric unit. The structure was solved by single isomor-
phous replacement with anomalous scattering (SIRAS) 
using potassium iodide. The final dataset was collected 
to 1.57  Å resolution, and the final model was refined 
to R = 22.6 % (Rfree = 26.3 %). Crystal parameters, data 
collection statistics, and refinement statistics are sum-
marized in Table  1. In the refined structure, myristoyl 
groups and their connections to the N-terminal gly-
cines were well-defined in the electron density map, as 
were the first 91 of 111 amino acid residues. The last 20 
residues (the C-terminus of the protein and the His-tag) 
lacked electron density, likely due to a disordered confor-
mation. The structure was deposited in the Protein Data 
Bank under PDB ID 4ZV5.
The asymmetric unit contains a dimer formed by two 
MA molecules. The structures of both MA subunits are 
virtually identical except for the position of the myristoyl 
group and the first five amino acids; the residual mean 
square deviation of Cα atoms for residues 7–92 is 0.306 Å 
(the N-terminal glycine is designated as residue 2). The 
monomeric subunit (Fig. 2) is a helical bundle comprising 
five alpha helices and a single-turn 310-helix (helix 5). The 
CTRS region (spanning residues 45–62) is accessible on 
the surface of the molecule in an orientation similar to 
that observed for M-PMV MA [14, 32]. Despite the low 
sequence similarity of retroviral MA proteins (Table  2), 
which precluded the use of the molecular replacement 
approach in the structure determination, the position 
and orientation of the helices follow the structural pat-
tern of other retroviral MA proteins.
Interestingly, the myristoyl group of one of the dimer-
forming MA molecules is not buried in the hydropho-
bic core of the protein chain to which it is covalently 
attached, as is common for the sequestered form of 
myr(+) MA proteins [28, 30–32]. Instead, the myristoyl 
group is sequestered in the hydrophobic pocket formed 
by the interface of both MA molecules in the asymmet-
ric dimer unit (Fig. 3). This interface is formed predomi-
nantly by helices 1 and 3. However, the myristoyl group of 
the second MA molecule in the dimer extrudes into the 
Fig. 1 Dynamic equilibrium of myristoylated myr(+) and nonmyris-
toylated myr(−) MA sedimenting species analyzed by analytical 
ultracentrifugation. Normalized continuous size distributions (c(s)) 
resulting from sedimentation velocity analyses were compared for 
myr(−) and myr(+) MAs at concentrations of 0.5 and 5.0 mg/mL. The 
percentages of monomeric, dimeric, and higher forms for individual 
MA forms in a single experiment are indicated above the peaks
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neighboring dimer unit. Therefore, the two nearest dimer 
units in the crystal are interconnected by two myristoyl 
groups, forming a tetramer of MA molecules around 
the two-fold axis of the P3121 space group (Fig.  3a, 
b). Regardless of the dimer unit to which the myristoyl 
groups are covalently attached, their positions in the 
hydrophobic interface are virtually symmetrical (Fig. 3c).
To analyze the relevance of the oligomeric organiza-
tion in the protein crystal, we used PDBePISA [38], an 
interactive tool for the exploration of macromolecular 
interfaces. The PISA software detected several interfaces, 
of which the largest was 945 Å2 per MA monomer. The 
dominant interface lies between the two MA molecules 
in the single asymmetric unit. We did not identify any 
significant interface between MA dimers, with the excep-
tion of the interface represented solely by interconnect-
ing myristoyl groups.
Because myr(+) MMTV MA predominantly forms 
dimers in solution, as confirmed by analytical ultracentrifu-
gation analysis, the myristoyl swapping between the neigh-
boring asymmetric units appears to be a specific result of 
crystal packing. In solution, the extruded myristoyl group is 
likely inserted into the hydrophobic pocket of its own dimer, 
forming a symmetric dimer with swapped myristoyl groups.
Table 1 Crystal parameters, data collection statistics, and refinement statistics











Ii(hkl), where Ii(hkl) is the individual intensity of the ith observation of reflection hkl and 〈Ii(hkl)〉 is the average 
intensity of reflection hkl with summation over all data
b R-value = ||Fo| − |Fc||/|Fo|, where Fo and Fc are the observed and calculated structure factors, respectively
c Rfree is equivalent to R-value but is calculated for 5 % of the reflections chosen at random and omitted from the refinement process
d Determined by MolProbity
Crystal Native I− soaked Native
Data collection statistics
 Space group P3121 P3121 P3121






 Wavelength (Å) 1.5000 1.5000 0.9184
 Resolution (Å) 46.04–1.90 (2.01–1.90) 46.02–1.86 (1.97–1.86) 46.08–1.57 (1.66–1.57)
 Number of unique reflections 15674 (2178) 17201 (2727) 28486 (4526)
 Multiplicity 5.7 (5.2) 4.9 (3.9) 6.2 (5.7)
 Completeness (%) 98.4 (84.3) 99.7 (99.2) 99.7 (99.1)
 Ramerge 3.6 (20.1) 6.0 (32.8) 3.9 (66.7)
 Average I/σ(I) 29.9 (7.7) 15.9 (3.4) 23.9 (2.4)
 Wilson B (Å2) 30.6 35.5 30.3
Refinement statistics
 Resolution range (Å) 34.44–1.90 (1.95–1.90) 46.08–1.57 (1.61–1.57)
 No. of reflections in working set 14,890 (696) 25616 (1826)
 No. of reflections in test set 748 (36) 1423 (92)
 R value (%)b 26.0 (60.7) 22.6 (29.4)
 Rfree value (%)
c 32.4 (70.7) 26.3 (33.4)
 RMSD bond length (Å) 0.024 0.012
 RMSD angle (º) 2.66 1.6
 Number of atoms in AU 1534 1634
 Number of protein atoms in AU 1494 1512
 Number of water molecules in AU 40 94
 Mean B value (Å2) 23.4 24.2
Ramachandran plot statisticsd
 Residues in favored regions (%) 96.7 99.4
 Residues in allowed regions (%) 1.6 0.0
 PDB ID 4ZV5
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Molecular dynamics simulation and calculation 
of interaction energies support the myristoyl swapping 
model in MMTV MA dimer formation
Based on our experimental results, we propose that 
the swapping of myristoyl groups within the dimer is 
important for dimerization of MMTV MA. To support 
this proposal, we performed molecular dynamics (MD) 
simulations and calculated interaction energies for four 
theoretically possible MMTV MA dimers (Fig. 4). All the 
MD trajectories became stable after 6  ns of simulation. 
The root-mean-square deviations (RMSD) of the pro-
tein backbone fluctuated around 1  Å, while those of 
the myristoyl groups reached up to 1.7 Å in the case of 
dimer 3 (D3). Interaction energy calculations using the 
MM-PBSA approach showed the order of binding as 
follows: D2 (−130  kcal/mol, swapped myristoyls) >D1 
(−108  kcal/mol, the asymmetric unit) >D3 (−89  kcal/
mol, unswapped myristoyls) >D4 (−68  kcal/mol, non-
myristoylated). The results of the MD simulation indicate 
that myristoyl groups are energetically more favorable 
Fig. 2 Structure of myristoylated MMTV MA. a The amino acid sequence of MMTV MA with a C-terminal His-tag. The N-terminal glycine is desig-
nated as residue 2. C-terminal residues lacking detectable positions on the electron density map and therefore not involved in the structure below 
(20 C-terminal residues) are shown in italics. Individual sequences representing helices 1–6 are indicated with correspondingly colored lines. b Car-
toon diagram illustrating the helical arrangement of the MA monomer with two possible orientations of the myristoyl group: sequestered (myr1A) 
and exposed (myr1B)
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when swapped between the two dimer-forming MA mol-
ecules (Fig.  4, D2) than when unswapped (Fig.  4, D3). 
Furthermore, the absence of a single myristoyl group 
within the dimer interface causes the interaction energy 
to drop (Fig.  4, D1). To evaluate the relative contribu-
tion of individual residues to the dimerization, we per-
formed a per-residue decomposition of the MM-PBSA 
interaction energies. The results, summarized in Table 3, 
show that the summed contribution of the myristoyl 
groups is three-fold higher for swapped myristoyl groups 
(−35.3  kcal/mol) than for unswapped myristoyl groups 
(−11.7  kcal/mol), which is comparable to the summed 
contribution of the most strongly contributing amino 
acid residues (−10 to −18 kcal/mol). These results sup-
port myristoyl swapping within the dimer as a driver for 
dimerization of MMTV MA.
Mutations within the dimerization interface impair MMTV 
MA dimerization
To verify contribution of residues to MA dimerization, 
we mutated selected residues oriented to the interior of 
dimerization interface (Fig.  5). Because many residues 
from dimerization interface are located in the regions 
important for proper biological function of MMTV MA 
(myristoylation signal at the N-terminus, and cytoplas-
mic targeting/retention signal spanning residues 45–62 
[15]), our choice of the residues available for mutation 
was restricted. We selected residues L11, F12, and V15 
and prepared a triple mutant L11N/F12N/V15N (MA-
3N) in both myristoylated and nonmyristoylated form. 
Analytical ultracentrifugation analyses of purified mutant 
myr(+) and myr(−) MA mutants were performed at 
two concentrations (0.5 and 5.0  mg/mL) under condi-
tions identical to those used for WT MA. Figure 6 shows 
that mutations L11N, F12N, and V15N impaired MA 
dimerization. Contrary to the WT myr(−) MA, which 
partially formed dimers at the higher concentration, 
myr(−) MA-3N formed only monomers at both con-
centrations (s20,w = 1.53 S). At the higher concentration, 
myr(+) MA-3N formed only dimers (s20,w  =  2.20 S) 
whereas wild-type myr(+) MA also formed a small 
amount of tetramers (2  %). At the lower concentration, 
myr(+) MA-3N formed monomers (s20,w = 1.81 S; 52 %) 
and dimers (s20,w = 2.39 S; 48 %) in contrast to wild-type 
myr(+) MA, which formed only dimers. The effect of 
L11N/F12N/V15N mutations on dimerization of myr(+) 
MA was lesser compared to the contribution of myris-
toyl group to this process. These results show that myris-
toylation itself is required, but not sufficient for efficient 
MMTV MA dimerization. 
Mutations affecting MMTV MA dimerization also influence 
extracellular particle production
To analyze impact of the mutations affecting MA dimeri-
zation on MMTV particle production, we performed 
pulse-chase experiments in transiently transfected human 
embryonic kidney 293T cells. For MMTV particle pro-
duction, we used the chimeric proviral vector pSMt-HYB/
D26A, which contains the heterologous M-PMV LTR pro-
moter and a mutation inactivating the viral protease [11]. 
This construct facilitates detection of intracytoplasmic par-
ticles and it will be denoted hereafter as wild-type (WT).
Following transfection into 293T cells, WT and 
MA-3N mutant viruses were analyzed by metabolic labe-
ling for their ability to express stable Gag polyproteins 
and produce extracellular immature particles (Fig.  7). 
Particle-producing cells were pulse-labeled for 1  h and 
chased for 12  h. Similar levels of stable Gag precursors 
were synthesized in all transfected cells and extracellular 
particles were observed for WT and mutant virus as well. 
As shown in Fig. 7a, the amount of pelletable structures 
in media produced by MA-3N mutant was lower than 
those produced by WT virus. To measure the relative 
efficiency of particle formation, the amount of extracel-
lular assembled Gag as a fraction of total Gag expressed 
in cells was determined for each construct and then com-
pared with that of WT (Fig. 7b). MA-3N virus produced 
particles with approximately half the efficiency of WT.
Table 2 Comparison of myristoylated MMTV MA with other retroviral MAs
a Root mean square deviation of Cα-atoms
b Number of aligned residues for structural alignment
c Sequence identity and similarity, respectively, determined by global alignment using the Needle-Wunsch algorithm on the EMBL-EBI website with default 
parameters (http://www.ebi.ac.uk/Tools/psa/)
Genus Species PDB ID Method RMSDa Nb %idc %simc
alpha RSV 1A6S NMR 4.68 72 13 19
beta M-PMV 2F76 NMR 3.49 80 27 51
gamma MoMuLV 1MN8 X-ray 4.67 80 15 31
delta HTLV -2 1JVR NMR 4.57 72 12 20
lenti HIV-1 1HIW X-ray 4.46 72 9 15
Page 7 of 15Doležal et al. Retrovirology  (2016) 13:2 
To verify the results obtained in human 293T cells, we 
used the rat mammary cell line RBA, which is suitable for 
production of MMTV upon transient transfection [39]. 
Because the expression level of MMTV proteins is signifi-
cantly lower in RBA cells than in 293T cells, we examined 
the accumulation of assembled Gag in culture media by 
Western blot analysis after 48 h of production in trans-
fected cells (Fig. 8). Proteins were separated on 15 % SDS 
PAGE gels and detected with a rabbit anti-MMTV cap-
sid polyclonal antibody. Under these conditions, we were 
able to detect extracellular pelletable structures for both 
WT and MA mutant and as expected, the particle release 
of MMTV MA-3N from RBA cells was reduced. These 
results suggest that MMTV bearing mutations L11N, 
F12N and V15N in the MA domain exhibits reduced effi-
ciency of extracellular particle production.
To further investigate the effect of impaired MA 
dimerization on extracellular particle production, we 
analyzed transiently transfected 293T cells expressing 
WT and MA-3N virus by transmission electron micros-
copy (TEM) (Fig.  9). In contrast to the WT produc-
ing cells, only a minimum of particles budding from the 
plasma membranes and accumulation of both isolated 
and clusters of assembled particles were observed in cells 
expressing the MA-3N mutant virus. Aberrantly formed 
particles were detected with a low frequency similar for 
both WT and MA-3N MMTV. These observations sug-
gest a reduced efficiency of the intracellular transport as 
an explanation for the partial defect of extracellular parti-
cle production in MA-3N mutant virus.
Discussion
Here, we demonstrated that myristoylation stimulates 
dimerization of MMTV MA and identified structural 
requirements for this interaction. Molecular dynamics 
modeling based on our experimentally determined struc-
ture of myr(+) MA confirmed the key role of the myris-
toyl group for dimer formation and revealed energetically 
favorable binding of the myristoyl group within the dimer 
interface. Myristoylated MMTV MA shares structural 
similarity with other retroviral MAs, but it differs in the 
orientation of the sequestered myristoyl group. In other 
myr(+) MAs characterized to date, the myristoyl group 
is sequestered in the hydrophobic core of the molecule to 
which it is covalently attached [28, 30–32]. In contrast, 
the myristoyl group of MMTV MA is entirely buried in 
the dimerization interface between two MA molecules. 
Moreover, dimerization of MMTV MA supports the 
sequestered conformation of the myristoyl, which con-
trasts with the myristoyl switch model based on HIV-1 
MA, in which oligomerization supports its extrusion [9].
Despite the fact that extrusion of one myristoyl group 
from one MMTV MA dimer unit to the neighboring 
asymmetric unit appears to be the result of crystal pack-
ing, it demonstrates an important aspect related to MA 
function. The process by which one MMTV MA mol-
ecule adopts an exposed myristoyl group conformation 
is analogous to the myristoyl switch model, in which the 
MA domain of a retroviral Gag polyprotein interacts 
with phospholipid membranes [30] and stimulates Gag 
multimerization. Thus, our results indicate that myr(+) 
Fig. 3 Organization of MMTV MA molecules in the crystal unit. a 
Schematic illustration of two dimer-forming MA molecules (red and 
green) that are connected with the neighboring dimer (grey) by 
swapping two myristoyl groups (red and grey). b Cartoon diagram 
illustrating the MA tetramer in an orientation perpendicular to the 
two-fold axis of symmetry. The color of individual myristoyl groups 
follows the same color scheme as in a. c Positions of both myristoyl 
groups in the hydrophobic pocket formed by the dimer interface 
are virtually identical regardless of the MA subunit to which they are 
covalently attached
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MMTV MA can adopt both sequestered and exposed 
conformations analogous to those described for myr(+) 
HIV-1 MA.
The MMTV MA dimer interface forms a deep hydro-
phobic pocket that is energetically favorable for myris-
toyl binding. Our data from analytical ultracentrifugation 
clearly show that the myristoyl group stimulates MA 
dimer formation at high and low protein concentrations. 
The absence of the myristoyl group reduces the amount 
of MA dimer in solution even at high protein concen-
tration (5  mg/mL). At a ten-fold lower concentration, 
myr(−) MA does not dimerize. It appears that the myris-
toyl group actively participates in formation of the dimer 
interface by interconnecting both monomeric MMTV 
MA units and that hydrophobic interactions are primar-
ily responsible for dimer stability. Accordingly, no homo-
typic interactions were detected when myr(−) MMTV 
MA protein fused at the N-terminus with a reporter 
domain was tested for self-association in the yeast two-
hybrid system [40]. Mutations of residues from dimeri-
zation interface (L11N/F12N/V15N), designed according 
to the MA crystal structure and molecular dynamic 
calculations, resulted in decreased MA dimerization. 
Interestingly, these mutations influenced also transport 
Fig. 4 Schematic illustration of theoretical dimer formations adopted 
by the myristoylated MMTV MA and their calculated interaction 
energies. D1 the asymmetric unit from the crystal structure, D2 sym-
metric dimer with swapped myristoyls, D3 symmetric dimer with 
unswapped myristoyls, D4 symmetric dimer without myristoyl groups
Table 3 Contribution of individual residues to the dimerization of MMTV MA
First twenty residues with the lowest energy
a Chain
b Energy in kcal/mol
D1 D2 D3 D4
Ca Residue Eb C residue E C Residue E C Residue E
A Myr 1 −14.5 A Myr 1 −18.0 A Arg 18 −8.5 A Arg 18 −9.6
B Leu 11 −6.4 B Myr 1 −17.3 B Arg 18 −6.7 A Leu 11 −4.9
A Arg 23 −5.6 A Arg 18 −9.0 B Leu 11 −6.0 B Leu 11 −4.8
B Leu 52 −5.3 B Arg 18 −9.0 B Myr 1 −5.9 A Lys 10 −4.7
A Leu 52 −5.2 A Leu 11 −5.7 A Leu 11 −5.9 B Lys 10 −4.5
B Lys 10 −5.2 B Leu 11 −5.7 A Myr 1 −5.8 B Leu 52 −4.5
A Lys 10 −4.8 B Lys 7 −5.1 A Lys 10 −4.7 A Leu 52 −4.5
B Arg 23 −4.6 B Leu 52 −4.8 B Lys 10 −4.6 A Lys 7 −2.3
A Leu 11 −4.5 A Lys 10 −4.7 A Leu 52 −4.4 B Glu 48 −2.1
B Arg 18 −3.7 B Lys 10 −4.6 B Leu 52 −4.4 A Asp 56 −2.1
B Lys 7 −3.3 A Leu 52 −4.6 A Glu 48 −3.0 B Lys 7 −2.0
B Val 15 −3.0 A Val 15 −3.0 A Lys 7 −2.7 B Val 15 −2.0
A Lys 7 −2.9 B Val 15 −3.0 B Lys 7 −2.6 B Asp 56 −2.0
A Glu 22 −2.8 A Lys 7 −2.5 B Glu 48 −2.6 A Val 15 −2.0
A Arg 18 −2.6 A Glu 48 −2.4 A Val 15 −2.3 B Glu 22 −1.8
B Ser 14 −2.3 A Gly 2 −2.2 B Val 15 −2.2 B Gly 8 −1.7
B Glu 48 −2.0 B Gly 8 −2.0 B Gly 8 −1.9 B Ser 14 −1.6
B Leu 19 −1.9 B Gly 2 −2.0 A Gly 8 −1.7 A Glu 48 −1.6
B Gly 8 −1.8 B Asp 56 −2.0 A Glu 22 −1.6 A Gly 8 −1.5
A Val 15 −1.7 A Gly 8 −1.9 A Ser 14 −1.5 A Ser 14 −1.4
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of assembled particles to PM and resulted in decreased 
production of extracellular particles. The current model 
describing the relocation of betaretroviral particles to PM 
involves anterograde transport mediated by microtubule-
associated Env-containing vesicles [18, 41–43]. However, 
a detailed mechanism of this transport is not yet fully 
understood. These questions remain to be investigated.
Myristoylation has been demonstrated to influence 
oligomerization of HIV-1 MA in solution; myr(−) MA 
is monomeric and myr(+) MA resides in monomer-
trimer equilibrium [30]. Despite a known tendency of 
retroviral MAs to form dimers or trimers at high protein 
concentrations, they are predominantly monomeric in 
solution. To date, the only oligomeric state of a retrovi-
ral MA protein proven to be biologically relevant is the 
trimer initially discovered in the crystal structures of 
myr(−) simian immunodeficiency virus (SIV) MA [21] 
and myr(−) HIV-1 MA [33]. NMR spectroscopy showed 
that in solution, myr(+) HIV-1 MA also has a tendency 
to form trimers analogous to those observed in the crys-
tal structures [30]. Although it was shown that myris-
toylation positively influences trimerization [30], the 
contribution of the myristoyl group to the trimerization 
of HIV-1 MA is of a different nature than our model 
proposes for dimerization of MMTV MA. In the HIV-1 
trimer, the myristoyl groups are exposed and positioned 
outside of the trimer interface and thus cannot partici-
pate in its formation (Fig. 10).
In betaretrovirus assembly, there is no apparent 
requirement for MA interaction with the PM, and intra-
cytoplasmic formation of immature particles instead 
relies on the internal scaffolding functions of domains 
located N-terminal to capsid protein [39, 40, 44–47]. In 
contrast to HIV-1 MA, the oligomerization capacity of 
betaretroviral M-PMV MA, which is capable of form-
ing dimers and trimers in its myr(−) form [34, 48], is not 
stimulated by myristoylation [32]. Instead, the structural 
changes caused by the sequestered myristoyl negatively 
affect the oligomerization of the MA molecule. It was 
suggested that the oligomerization capacity of M-PMV 
MA is restored by conformational changes induced by 
the binding of MA to the membrane [32]. These differ-
ences from myristoyl-stimulated dimerization of MMTV 
MA suggest that betaretroviruses may have developed 
different strategies to sequester the MA myristoyl group 
until it needs to adopt an exposed conformation for 
membrane binding.
Conclusions
We provide experimental data demonstrating that dimer-
ization of MMTV MA is stimulated by its myristoylation. 
We clarified the molecular mechanism of this stimula-
tion by determining the crystal structure of the myr(+) 
MMTV MA protein. Based on structural data and molec-
ular modeling, we propose a model for symmetric dimer 
formation of myr(+) MMTV MA in solution. Our mech-
anism describing how dimerization of MMTV MA relies 
on swapped myristoyl groups represents a novelty not 
only among retroviral MA proteins but also for dimeri-
zation of any myristoylated protein. Our model sug-
gests that oligomerization of betaretroviral MA protein 
is accompanied by sequestration of the myristoyl group 
that participates in the formation of the interaction inter-
face. Although it contrasts with the model proposed for 
HIV-1 and other retroviruses that assemble with mem-
brane support, our model is well-suited for intracyto-
plasmic betaretroviral assembly. Biological experiments 
further indicated that proper MA dimerization is impor-
tant for efficient MMTV particle release.
Methods
DNA constructs
Plasmid pET22-MA-His used for the bacterial expres-
sion of MMTV MA protein was described previously 
[37]. Mutations of residues 11L, 12F and 15V to aspara-
gines were introduced by PCR into pSMtv [11] plasmid 
Fig. 5 Cartoon diagram of myr(+) MA dimer showing positions of 
residues L11, F12, and V15. The residues are shown in yellow, myristoyl 
groups in red, and CTRSs in blue. Residues L11 and V15 are oriented 
towards the neighboring monomer whereas residue F12 is oriented 
towards the myristoyl group from the neighboring monomer. CTRS 
forms an important part of the dimerization interface
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containing MMTV gag gene sequence using forward 
mutagenic primer 5′-TGGGGGTCTCGGGCTCAAAA 
GGGCAGAAAAACAATGTTTCTAATTTACAAA 
GGCTCCTCTCAGAGAGGGGTC-3′ in combination 
with reverse primer 5′-TTTCAATGGCAGCGGTTCC 
C-3′ and pSMtv as template. Resulting PCR product was 
cleaved with AvaI–PflMI and ligated into pSMtv vec-
tor digested  in the same way to produce pSMtv-MA-
3N shuttle vector. Mutated gag sequence was used as a 
template for PCR using primers MA-Nde-F and MA-
6H-Xho-R and the resulting mutant MA sequence was 
cleaved with NdeI–XhoI enzymes and ligated into iden-
ticaly prepared pET22b vector for the bacterial expres-
sion. The primer sequences used for this subcloning will 
be available upon request. In parallel, the complete gag 
sequence carrying the desired mutations was subcloned 
from pSmtv-MA-3N plasmid using KasI–XbaI enzymes 
and subcloned into identicaly treated MMTV proviral 
construct pSMt-HYB/D26A [11]. All DNA segments 
resulting from PCR were verified by sequencing.
Expression and purification of recombinant MMTV MA 
protein
Recombinant myr(−) and myr(+) MMTV MA proteins 
were expressed and purified as previously described [37]. 
The molecular masses of the proteins were analyzed by 
mass spectrometry (MALDI TOF/TOF) as previously 
described [37]. To approximately determine the mini-
mal detectable amount of myr(−) MA in the sample of 
myr(+) MA, we mixed a sample of myr(+) MA which 
we considered “100  %” myristoylated with a sample of 
myr(−) in the ratio 1000:1 (2:0.002 mg/mL) and analyzed 
the mixture by mass spectrometry (Additional file  1: 
Fig. 6 Dynamic equilibrium of the L11N/F12N/V15N triple mutant of 
myr(+) and myr(−) MA sedimenting species analyzed by analytical 
ultracentrifugation. Normalized continuous size distributions (c(s)) 
resulting from sedimentation velocity analyses were compared for 
myr(−) and myr(+) MAs at concentrations of 0.5 and 5.0 mg/mL. The 
percentages of monomeric, dimeric, and higher forms for individual 
MA forms in a single experiment are indicated above the peaks
Fig. 7 Mutations L11N, F12N and V15N in MA domain (MA-3N) reduce extracellular MMTV particle production. a Pulse-chase analysis of immature 
MMTV particles produced in transfected 293T cells. Cells expressed wild-type MMTV (WT) and the virus with the mutation in MA domain of Gag 
(MA-3N); M mock-transfected cells. Cells were labeled for 1 h with [35S]methionine and [35S]cysteine (lanes 1–3) and then chased for 12 h (lanes 
4–5). At both time points, cells were harvested, lysed, and subjected to immunoprecipitation. Released particles (lanes 6–7) were collected from 
the culture media by ultracentrifugation through a 20 % sucrose cushion. Viral proteins were immunoprecipitated with polyclonal rabbit anti-CA 
serum, separated on a 10 % SDS-PAGE gel, and subjected to phosphorimager analysis. b Comparative analysis of released particle production. The 
efficiency was expressed as a share of the signal from the released particulate Gag from the total amount of Gag synthesized. Mutant MA-3N is 
shown relative to the WT (set to 1). Each bar represents the average of results from three independent experiments, and standard error of the mean 
is shown
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Figure S1B). The 0.1 % concentration of myr(−) MA was 
detectable in the mixture and therefore we can state that 
the sample of myr(+) contained less than 0.1 % of myr(−) 
MA, which we suppose to not interfere with the subse-
quent analyses. After purification, the proteins were dia-
lyzed against 50 mM Na2HPO4, 300 mM NaCl, 2.5 mM 
TCEP, pH 6.0 (buffer A), and concentrated to an appro-
priate concentration by ultrafiltration using an Amicon 
Ultra 3K device (Millipore).
Analytical ultracentrifugation
Sedimentation velocity analyses were performed using a 
ProteomeLab XL-I analytical ultracentrifuge equipped 
with an An50Ti rotor (Beckman  Coulter). Protein sam-
ples were concentrated to 0.5 or 5.0 mg/mL in buffer A, 
which was also used as a reference buffer. The experi-
ments were carried out at 50,000  rpm and 4  °C; 200 
absorbance scans were recorded at 6 min intervals with 
30 µm spatial resolution at 280 nm for the diluted sam-
ples and at 250 nm for the concentrated samples with 12 
and 3 mm Epon centerpieces, respectively. Buffer density 
and protein partial specific volume were estimated in 
SEDNTERP 1.09 (http://www.jphilo.mailway.com). Data 
were analyzed with SEDFIT 14.1 [49] using a c(s) con-
tinuous size distribution model. The approximate ratio of 
monomeric and dimeric forms was calculated from the 
peak areas.
Protein crystallization
Myristoylated MMTV MA was concentrated to a final 
concentration of 10  mg/mL. Initial crystallization tri-
als were performed with the help of a Crystal Gryphon 
crystallization workstation (Art Robbins Instruments) by 
sitting drop vapor diffusion method at 19  °C in 96-well 
plates; 0.2 μL protein solution was mixed with 0.2 μL res-
ervoir solution and the mixture was equilibrated over 200 
μL reservoir solution. The PEGs Suite and JSCG Core I 
Suite (QIAGEN) were used for the initial crystallization 
condition screen. Initial microcrystals appeared in sev-
eral days under the following conditions: 0.2  M potas-
sium chloride and 20 % PEG 3350. Further optimization 
involved changing to the hanging drop mode in 24-well 
crystallization plates (EasyXtal DG-Tool, QIAGEN). Final 
crystals were obtained by mixing 3 μL MMTV MA com-
plex solution with 1  μL reservoir solution composed of 
0.2 M potassium chloride and 20 % PEG 3350 as precipi-
tant, and these were directly cryocooled in liquid nitro-
gen. For the phasing experiment, crystals were soaked for 
10 min in a solution of 0.2 M potassium iodide and 20 % 
PEG 3350 and cryocooled in liquid nitrogen.
Data collection and structure determination
Diffraction data for phasing were collected using a 1.5 Å 
wavelength for native and iodide-soaked crystals. Data 
were collected to 1.9 Å resolution at 100 K for both data-
sets. The native dataset for the final structure was col-
lected using a 0.9184 Å wavelength at 100 K. All datasets 
were collected at the MX14.2 beamline at BESSY, Berlin, 
Germany [50], and processed using the XDS program 
[51]. The structure was solved with SHELXC/D/E pro-
grams [52] using HKL2MAP GUI [53] or GUI for SHELX 
programs [54]. Macromolecular phasing was performed 
according to the SIRAS method, using datasets from the 
native crystal and crystal soaked in potassium iodide 
(both measured using a 1.5  Å wavelength). The initial 
model was improved and rebuilt with the program Buc-
caneer [55]. This was followed by manual rebuilding with 
COOT [56] and refinement with Refmac5 [57] using the 
native dataset measured at 1.5 Å wavelength. At the end 
of this stage, the refinement statistics were as follows: 
R = 26.0 % (Rfree = 32.4 %). The final model, calculated 
from the dataset measured at 0.9184 Å wavelength, was 
refined to R = 22.6 % (Rfree = 26.3 %). The crystal param-
eters, data collection statistics, and refinement statistics 
are summarized in Table 1.
Molecular dynamics simulation and calculation 
of interaction energies
Four possible dimers were derived from the crystal struc-
ture of myr(+) MMTV MA (Fig. 4). The first dimer (D1) 
was the asymmetric unit without any modifications. The 
Fig. 8 Western blot analysis of MMTV particles produced by rat 
mammary cells (RBA) transiently transfected with pSMt-HYB/
D26A-derived constructs containing inactive viral protease. RBA 
cells expressed wild-type MMTV (WT: lanes 2, 5) and virus with the 
mutated MA domain of Gag (MA-3N: lanes 3, 6). Lanes 1 and 4 repre-
sent samples from mock-transfected cells. At 48 h post-transfection, 
cells were harvested and directly lysed in SDS protein loading buffer 
(Cell Lysate). The extracellular virus particles were isolated from 
culture media by ultracentrifugation through a 20 % sucrose cushion 
(Medium) and pellets were dissolved in SDS protein loading buffer. 
Proteins were separated on a 15 % SDS-PAGE gel and detected by 
Western blot assay using polyclonal anti-MMTV CA antiserum. The 
migration position of MMTV Gag is indicated
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second dimer (D2) was derived from the asymmetric unit 
by connecting the myristoyl group from monomer 2B 
to monomer 1B (Fig.  3a), which yielded a pseudo-sym-
metric dimer with swapped myristoyl groups. The third 
dimer (D3) was derived from D2 by swapping the con-
nections of the proteins to the myristoyl groups, which 
yielded a dimer with unswapped myristoyl groups. The 
fourth dimer (D4) was derived from D2 by removing the 
myristoyl groups.
The systems were prepared for molecular dynam-
ics (MD) simulations essentially as previously described 
[58], with a few modifications. The two histidine residues 
(both located on the protein surface far from the inter-
face) were modeled in the Nε monoprotonated state. This 
setup was created in the LEaP module of AMBER14 [59]. 
The amino acid parameters were taken from the ff14SB 
AMBER force field [60], and the myristoyl parameters 
were obtained using RESP charge fitting [61] and GAFF 
parameters [62]. Chloride counterions were added to the 
solvated dimers to neutralize the total charge (four for 
D1–D3 and six for D4).
The initial relaxation included optimization of the 
myristoyl and Gly2 residues in 250 cycles of steepest 
descent. The other minimization steps, warming, and 
equilibration MD followed a previously described pro-
tocol [58]. The length of production MD was 10  ns. 
Monomer–monomer interaction energies were calcu-
lated using the MM-PBSA module of AMBER14 on 100 
snapshots of the last 4 ns of the simulation. The Poisson-
Boltzmann equation was solved, and Debye–Hückel 
screening with 150  mM ionic strength was used. The 
solvent-accessible surface-area-dependent term was 
employed for nonelectrostatic solvation free energies. 
The interaction energies were decomposed on a per-res-
idue basis so that 1–4 interactions were added to either 
electrostatic or van der Waals contributions.
Fig. 9 Thin-section EM analysis of immature intracytoplasmic MMTV particles formed by wild-type MMTV virus (WT) and the virus with the muta-
tion in MA domain (MA-3N) in transfected 293T cells. Black arrows indicate immature viral particles. Bars correspond to 1 µm
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Cell lines and transfections
Human kidney embryonic cells 293T (ATCC) and rat 
mammary cells RBA (ATCC) were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented 
with 10  % fetal bovine serum  and 20  mM l-glutamine 
(Sigma Aldrich). 293T cells were transfected by FuGENE 
HD (Roche Molecular Biochemicals) reagent and RBA 
cells were transfected using Lipofectamine LTX rea-
gent (Invitrogen), both according to the manufacturer’s 
instructions.
Metabolic labeling and immunoprecipitation
Cells were grown on 60  mm culture dishes, 24  h post-
transfection were 3 times washed with PBS buffer 
and then pulse-labeled for 60  min at 37  °C in 1  mL of 
DMEM without methionine and cysteine supplemented 
with 100  µCi of [35S]methionine-[35S]cysteine protein-
labeling mix (MP Biochemicals). The label was chased 
for the desired period of time by replacing the labeling 
medium with complete DMEM. For analysis of total 
intracellular viral proteins, the cells were lysed in buffer 
containing 0.15 M NaCl, 50 mM Tris–HCl (pH 7.5), 1 % 
Triton X-100, and 1 % deoxycholate (Lysis Buffer). Cellu-
lar debris and nuclei were removed by centrifugation for 
1 min at 14,000 rcf. The lysate was then adjusted to 0.1 % 
SDS and the cell-associated viral proteins were immu-
noprecipitated by rabbit polyclonal anti-CA antiserum 
for 1  h and after addition of protein A immobilized on 
Sepharose beads (Invitrogen) the suspension was incu-
bated for 2 h. For analysis of released virus particles, tis-
sue culture medium was first filtered through a 0.45 μm 
filter. Particles were then collected by centrifugation 
through a 20 % w/v sucrose cushion at 35,000 rpm for 1 h 
in a SW 41 Ti rotor (Beckman Coulter). Pelleted virions 
were dissolved in Lysis Buffer containing additional 0.1 % 
SDS and the virus-associated proteins were immunopre-
cipitated as described for cell lysates. Immunoprecipi-
tates were examined by separation on 10  % SDS-PAGE 
gels followed by phosphorimager analysis. Band intensi-
ties for Gag were acquired on a Typhoon system using 
ImageQuant software (Amersham).
Western blotting
Transiently transfected RBA cells were grown on 100 mm 
culture dishes and harvested 48  h post-transfection. 
Trypsinized cells were pelleted for 1  min at 14,000 rcf 
and resuspended in 0.1  ml PBS and 0.2  ml of SDS pro-
tein loading buffer (PLB 2×) Virions from the culture 
supernatants were collected as described above for 
metabolically labeled proteins and resulting pellets were 
resuspended in 30  μl of PLB (2×). Analyzed proteins 
were separated on  10  % SDS-PAGE gel, blotted onto a 
nitrocellulose membrane, and detected by using rabbit 
polyclonal anti-CA antibody.
Electron microscopy
Examined cells were washed in PBS and fixed by 3 % glu-
taraldehyde in 0.1 M cacodylate buffer, pH 7.4. The cells 
were postfixed  with 1  % osmium tetroxide, dehydrated 
in graded ethanol solutions and embedded in epoxy resin 
AGAR 100. Ultrathin sections (70 nm) were stained with 
uranyl acetate and lead citrate. The samples were ana-
lyzed with a JEOL JEM-1200EX electron microscope 
operated at 60 kV.
Availability of supporting data
The structure of myristoylated MMTV MA protein was 
deposited in the Protein Data Bank under PDB ID 4ZV5.
Additional file
Additional file 1: Figure S1. MS MALDI TOF/TOF analysis of myris-
toylated, myr(+), and nonmyristoylated, myr(−), MMTV MA. (A) The 
sample of myristoylated MA contained myr(+) MA (m/z = 13006). The 
sample of nonmyristoylated MA contained myr(−) MA (m/z = 12795) and 
MA with uncleaved initial methionine (m/z = 12927). (B) To approximately 
determine the minimal detectable amount of myr(−) MA in the sample 
of myr(+) MA, the sample of myr(+) MA was mixed with the sample of 
myr(−) in the ratio 1000:1 (2:0.002 mg/mL). This amount of myr(−) MA 
was detectable whereas the sample of myr(+) contained no detectable 
amount of myr(−) MA.
Fig. 10 Position of the myristoyl groups within the HIV-1 MA trimer. 
The myristoyl groups (yellow) in the HIV-1 trimer do not participate in 
formation of the intermolecular interface. The model is based on the 
NMR structure of myr(+) HIV-1 MA (PDB ID 1UPH) superposed on the 
crystal structure of trimeric myr(−) HIV-1 MA (PDB ID 1HIW)
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